Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined With KRT-232 in Patients With Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia (AML)

NCT04669067 is registered in ClinicalTrials.gov with Telios Pharma, Inc. as lead sponsor.

NCT NCT04669067
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04669067 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined With KRT-232 in Patients With Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia (AML)
Lead sponsor
Telios Pharma, Inc.
Phase
Phase 1/2
Overall status
Unknown status
Start date
March 31, 2021
Completion date
November 30, 2025
Enrollment
18 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia